Abstracts

2007 International Consensus Conference on Pathogen Inactivation

Impact of Photochemical Treatment (INTERCEPT Blood System for Platelets, IBSP) on Platelet Use in Routine Practice: A Three Year Experience.  Click here to view abstract.

Impact of Photochemical Pathogen Inactivation Treatment (INTERCEPT Blood System for Platelets, IBSP) on the Response to Transfusion with 6 and 7- Day Old Components.  Click here to view abstract.

Platelet Components Treated with Pathogen Inactivation Using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Clinical Trial in Germany.  Click here to view abstract.

The Efficacy of Photochemical Treatment with Amotosalen and UVA (INTERCEPT) for Inactivation of T. cruzi in Buffy Coat Platelet Components.  Click here to view abstract.

Three Years of Routine Use Experience with the INTERCEPT Blood System for Platelets.  Click here to view abstract.

Pathogen Inactivation of Double Dose Apheresis Platelets Using INTERCEPT Blood System: Logistical and Financial Benefits and Clinical Efficacy.  Click here to view abstract. 

Three Years of Experience with the INTERCEPT Blood System for Apheresis Platelets in Routine Use.  Click here to view abstract.

The Effect of Photochemical Treatment (PCT) with Amotosalen and UVA Light on Coagulation Function of Concurrent Plasma from Platelet Apheresis.  Click here to view abstract.

Coagulation Function in Fresh Frozen Plasma Prepared with Two Photochemical Treatment Methods.  Click here to view abstract.

Implementation of Photochemical Inactivation (INTERCEPT Blood System for Platelets) in a Regional Blood Center.  Click here to view abstract.

Impact of Photochemical Pathogen Inactivation Treatment (INTERCEPT Blood System for Platelets, IBSP-PC) on the Response to Transfusion with 6 and 7 - Day Old Components.  Click here to view abstract.

 2007 International Society of Blood Transfusion (ISBT)

Inactivation of Chikungunya Virus in Plasma and Platelets Using the INTERCEPT Blood System.  Click here to view abstract.

Robustness of Viral Inactivation in High-Dose INTERCEPT Platelets.  Click here to view abstract.

Platelet Components Treated with Pathogen Inactivation Using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Clinical Trial in Germany.  Click here to view abstract.

Platelet Concentrates Treated for Pathogen Inactivation Using the INTERCEPT Blood System: Manufacturing and Quality Control of INTERCEPT Platelets in Routine Use.  Click here to view abstract.

A Comparison of Transfusion of Standard and Pathogen Inactivated (INTERCEPT) Platelets with Regards to CCI and Acute Transfusion Reactions in Hematological Patients.  Click here to view abstract.

2007 American Association of Blood Banks

Conservation of Human Platelet Antigen (HPA) Immunologic Identity After Photochemical Treatment of Platelet Concentrates with Amotosalen (S-59) and UVA Light.  Click here to view abstract.

Complement Factors H and I are Conserved in Plasma Pathogen Inactivated with Amotosalen and UVA Light.  Click here to view abstract.